Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNI91103 intranasal niclosamide in adults with asymptomatic or mildly symptomatic COVID-19
2021-001036-25Phase 2Terminated
- Sponsor
- UNION therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing UNI91103 intranasal niclosamide with Placebo intranasal (2 arms). Primary endpoint: Change from baseline in symptoms through Day 10. Started Apr 2021; status: terminated.
02
Drugs
niclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001036-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001036-25.